Design Therapeutics (DSGN) Cash from Investing Activities (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Cash from Investing Activities data on file, last reported at -$7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 196.43% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.5 million (down 76.12% YoY), and the FY2025 full-year result was $22.9 million, down 47.87% from the prior year.
• Cash from Investing Activities advanced to -$7.6 million in Q1 2026, from -$11.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $27.3 million in Q2 2024 to a low of -$157.0 million in Q2 2022.
• A 5-year average of -$6.4 million and a median of $5.6 million in 2023 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities plunged 1157.22% in 2022 and soared 4666.43% in 2023, its largest moves.
• Tracing DSGN's Cash from Investing Activities over 5 years: stood at -$1.1 million in 2022, then jumped by 626.04% to $5.6 million in 2023, then tumbled by 67.02% to $1.8 million in 2024, then plunged by 732.26% to -$11.6 million in 2025, then surged by 34.48% to -$7.6 million in 2026.
• Business Quant data shows DSGN's Cash from Investing Activities at -$7.6 million in Q1 2026, -$11.6 million in Q4 2025, and $6.5 million in Q3 2025.